SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test
Overview
The SLC25A22 gene is associated with Early infantile epileptic encephalopathy type 3 (EIEE3), a rare genetic disorder that affects the brain and causes seizures. This disorder typically begins in the first few months of life and is characterized by recurrent seizures, developmental delay, and intellectual disability.
Test Details
The SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test is a neurology-based genetic test offered by DNA Labs UAE. The test uses NGS (Next Generation Sequencing) technology to identify mutations in the SLC25A22 gene that are associated with EIEE3.
Components
- Price: 3200.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Neurological Disorders
- Doctor: Neurologist
- Test Department: Genetics
Pre Test Information
Before undergoing the SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected with EIEE3.
Procedure
The SLC25A22 Gene Early Infantile Epileptic Encephalopathy Type 3 Genetic Test requires a sample of the patient’s DNA. This can be obtained through a blood sample or a cheek swab. The DNA is then sequenced using NGS technology to identify any mutations in the SLC25A22 gene.
Implications and Treatment
If a mutation is identified, genetic counseling may be recommended to help the patient and their family understand the implications of the diagnosis. Treatment for EIEE3 typically involves medications to control seizures and supportive therapies to address developmental delays and other symptoms.
| Test Name | SLC25A22 Gene Early infantile epileptic encephalopathy type 3 Genetic Test |
|---|---|
| Components | |
| Price | 3200.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for SLC25A22 Gene Early infantile epileptic encephalopathy type 3 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with SLC25A22 Gene Early infantile epileptic encephalopathy type 3 |
| Test Details | The SLC25A22 gene is associated with Early infantile epileptic encephalopathy type 3 (EIEE3), a rare genetic disorder that affects the brain and causes seizures. This disorder typically begins in the first few months of life and is characterized by recurrent seizures, developmental delay, and intellectual disability. NGS (Next Generation Sequencing) genetic testing is a type of genetic testing that uses advanced technology to rapidly sequence large amounts of DNA. This type of testing can be used to identify mutations in the SLC25A22 gene that are associated with EIEE3. NGS genetic testing for EIEE3 typically involves collecting a sample of the patient’s DNA, which can be obtained through a blood sample or a cheek swab. The DNA is then sequenced using NGS technology to identify any mutations in the SLC25A22 gene. If a mutation is identified, genetic counseling may be recommended to help the patient and their family understand the implications of the diagnosis and to discuss any treatment options that may be available. Treatment for EIEE3 typically involves medications to control seizures and supportive therapies to address developmental delays and other symptoms. |
